JP2016522194A5 - - Google Patents

Download PDF

Info

Publication number
JP2016522194A5
JP2016522194A5 JP2016513128A JP2016513128A JP2016522194A5 JP 2016522194 A5 JP2016522194 A5 JP 2016522194A5 JP 2016513128 A JP2016513128 A JP 2016513128A JP 2016513128 A JP2016513128 A JP 2016513128A JP 2016522194 A5 JP2016522194 A5 JP 2016522194A5
Authority
JP
Japan
Prior art keywords
optionally substituted
composition
compound according
subject
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016513128A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016522194A (ja
JP6492060B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/037548 external-priority patent/WO2014183068A2/en
Publication of JP2016522194A publication Critical patent/JP2016522194A/ja
Publication of JP2016522194A5 publication Critical patent/JP2016522194A5/ja
Priority to JP2019038815A priority Critical patent/JP6914287B2/ja
Application granted granted Critical
Publication of JP6492060B2 publication Critical patent/JP6492060B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016513128A 2013-05-10 2014-05-09 肺状態および他の状態の処置 Expired - Fee Related JP6492060B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019038815A JP6914287B2 (ja) 2013-05-10 2019-03-04 肺状態および他の状態の処置

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361822224P 2013-05-10 2013-05-10
US61/822,224 2013-05-10
PCT/US2014/037548 WO2014183068A2 (en) 2013-05-10 2014-05-09 Treatment of pulmonary and other conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019038815A Division JP6914287B2 (ja) 2013-05-10 2019-03-04 肺状態および他の状態の処置

Publications (3)

Publication Number Publication Date
JP2016522194A JP2016522194A (ja) 2016-07-28
JP2016522194A5 true JP2016522194A5 (enExample) 2017-06-22
JP6492060B2 JP6492060B2 (ja) 2019-03-27

Family

ID=51867886

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016513128A Expired - Fee Related JP6492060B2 (ja) 2013-05-10 2014-05-09 肺状態および他の状態の処置
JP2019038815A Expired - Fee Related JP6914287B2 (ja) 2013-05-10 2019-03-04 肺状態および他の状態の処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019038815A Expired - Fee Related JP6914287B2 (ja) 2013-05-10 2019-03-04 肺状態および他の状態の処置

Country Status (8)

Country Link
US (2) US9862690B2 (enExample)
EP (1) EP2994464B1 (enExample)
JP (2) JP6492060B2 (enExample)
CN (2) CN108721295B (enExample)
AU (1) AU2014262471B2 (enExample)
CA (1) CA2912057C (enExample)
IL (1) IL242516B (enExample)
WO (1) WO2014183068A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014183068A2 (en) * 2013-05-10 2014-11-13 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Treatment of pulmonary and other conditions
CN105566241B (zh) * 2016-01-18 2018-05-25 中国药科大学 1-磺酰胺基-4-芳氧基类化合物、制备方法及其医药用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4313948A (en) * 1980-11-20 1982-02-02 E. R. Squibb & Sons, Inc. Hypotensive imidazole substituted mercapto-1-oxopropyl-L-prolines
JPS63139339A (ja) * 1986-12-02 1988-06-11 Canon Inc 記録媒体
US5672731A (en) 1994-05-20 1997-09-30 Air Products And Chemicals, Inc. N-vinylformamide/alkyl acrylate Michael adducts
ZA977103B (en) * 1996-08-09 1999-02-08 Eisai Co Ltd Benzopiperidine derivatives
US6747055B1 (en) 1998-07-17 2004-06-08 The United States Of America As Represented By The Department Of Health And Human Services Water-soluble drugs and methods for their production
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
WO2004043349A2 (en) 2002-11-06 2004-05-27 Bristol-Myers Squibb Company Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme
US7351720B2 (en) 2003-06-12 2008-04-01 Bristol-Myers Squibb Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
EP1656936A4 (en) * 2003-08-06 2010-03-17 Signal Creation Inc Macrophage activation INHIBITORS
US20060276536A1 (en) * 2004-02-12 2006-12-07 Vander Jagt David L Cancer treatment using curcumin derivatives
WO2007098504A1 (en) * 2006-02-24 2007-08-30 Emory University Prodrugs of curcumin analogs
CA2657114A1 (en) * 2006-07-20 2008-01-24 Otsuka Pharmaceutical Co., Ltd. Nf-.kappa.b inhibitor
TWI387585B (zh) 2006-09-01 2013-03-01 Dow Agrosciences Llc 殺蟲性之n-取代(雜芳基)烷基烴基硫亞胺
EP2170311A4 (en) * 2007-05-16 2011-10-19 Avalon Pharmaceuticals COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING AUTOIMMUNE DISEASES
CN101344958A (zh) 2007-07-09 2009-01-14 上海华燕房屋经纪有限公司 网络独立经纪人系统与方法
US9242011B2 (en) 2008-04-01 2016-01-26 Novo Nordisk A/S Insulin albumin conjugates
CA2744388A1 (en) * 2008-11-21 2010-05-27 The Johns Hopkins University Compositions and methods for treating or preventing radiation injury
CN101475532B (zh) * 2009-02-10 2011-07-20 贵州大学 1,5-二杂环基-1,4-戊二烯-3-酮衍生物及制备方法和用途
WO2010127058A1 (en) * 2009-05-01 2010-11-04 Profectus Biosciences, Inc. Benzamide and naphthamide derivatives inhibiting nuclear factor- kap pa (b) - (nf-kb)
US9174960B2 (en) * 2009-09-18 2015-11-03 Centre National De La Recherche Scientifique Compounds useful against kinetoplastideae parasites
CN103086958A (zh) * 2011-11-04 2013-05-08 中国科学院上海药物研究所 NFκB通路激活抑制剂、其制备方法、药物组合物及用途
WO2014183068A2 (en) * 2013-05-10 2014-11-13 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Treatment of pulmonary and other conditions

Similar Documents

Publication Publication Date Title
JP2016534153A5 (enExample)
EP2970089B1 (en) Substituted aromatic compounds
JP2017505761A5 (enExample)
JP2015517489A5 (enExample)
JP2019507781A5 (enExample)
JP2016500111A (ja) 肺疾患の処置
JP2016516808A5 (enExample)
WO2009050726A3 (en) Compositions and methods for improved delivery of bupropion
EP4245368A3 (en) Migraine prevention and treatment
JP2016510012A5 (enExample)
JP2016511753A5 (enExample)
CN107708697B (zh) 纤维化病治疗剂
EP4591936A3 (en) Treatment of respiratory diseases
WO2014016548A3 (en) Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient
JP2018538273A5 (enExample)
JP2016510326A5 (enExample)
JP2013538857A5 (enExample)
JP2016519106A5 (enExample)
CN103857394A (zh) 四氢甲基嘧啶羧酸的治疗应用
JP2018505187A5 (enExample)
JP2022506716A5 (enExample)
CN106488770A (zh) 用于治疗copd的福莫特罗和布地奈德的组合
JP2016210814A (ja) カルボン酸フェニルケトン化合物およびその薬学的使用
JP2019507182A5 (enExample)
JP2008514733A (ja) 標的化プロテアーゼインヒビターによる、外傷性もしくは変性性の神経疾患、耳科疾患または眼科疾患の処置